Stock Analysis
Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis
Aurinia Pharmaceuticals Inc. (AUPH) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Aurinia Pharmaceuticals Inc. (AUPH) currently has an AIQ Score of 75/100, indicating a bullish setup. Value is the strongest factor at 84/100. Risk is the weakest current factor at 68/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
AUPH at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $15.73 |
| AIQ Score | 75/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $2.1B |
| P/E Ratio (TTM) | 6.64 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $0.24 |
| Revenue (Q3 FY2026) | $83.7M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.64 |
| Volume | 691.3K |
| 52-week range | $13.52-$19.25 |
| RSI 14 | 39.95 |
| 50-Day SMA | $16.48 |
| 200-Day SMA | $15.73 |
| Analyst Price Target | $18.00 |
| Next Earnings | Feb 25, 2027 |
AUPHAurinia Pharmaceuticals Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum73
- Value84
- Quality77
- Risk resilience68
- Sentiment—
AUPH Stock Analysis Summary
Aurinia Pharmaceuticals Inc. (AUPH) currently has an AIQ Score of 75/100, indicating a bullish setup. Value is the strongest factor at 84/100. Risk resilience is the weakest current factor at 68/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, AUPH has AIQ Score of 75/100 with Value base of 84/100 and fading Risk resilience at 68/100. Wait for component alignment before adding exposure.
Healthcare · -2.96% stock move · AUPH classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is AUPH Bullish or Bearish Right Now?
AUPH currently has a bullish overall setup. Value is the strongest factor at 84/100, while Risk Resilience is weakest at 68/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 77/100.
- - Momentum is constructive at 73/100.
- - Risk Resilience is supportive at 68/100.
- - Analyst target implies +14.43% upside from the latest quote.
- - Price is -0.00% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (34 vs 7).
Current Consensus
AUPH's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 5 neutral, and 34 sell votes. AUPH's 14-day RSI is 39.95, which places the stock in a weaker momentum range. AUPH's beta is 0.64, indicating lower market sensitivity than the broad market.
What Changed in AUPH?
The largest recent change in AUPH is Momentum moving down by 4.0 points over the available 7-day comparison window. Value remains the strongest visible factor.
What Would Change the AUPH Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
AUPH Decision Framework
Public evidence layers, setup checks, and risk context for Aurinia Pharmaceuticals Inc..
Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis
Aurinia Pharmaceuticals Inc. has an AIQ Score of 75/100 in a Bullish regime. Value is strongest at 84/100. Beta is 0.64, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | AUPH is in a Bullish AIQ regime with score 75/100. |
| Signal Conflict | The primary conflict is that value leads at 84/100 while risk lags at 68/100. |
| Factor Evidence | Momentum 73/100 · Value 84/100 · Quality 77/100 · Risk 68/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 84/100.
Momentum is 73/100 and RSI (14) is 39.9.
AUPH is in a Bullish regime at 75/100.
Risk factor is 68/100 with beta 0.64 and annual volatility 35.53%.
Current conflict: value leads at 84/100 while risk lags at 68/100.
AUPH Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
AUPH Fundamentals
AUPH valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
AUPH Technical Analysis
AUPH technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
AUPH Stock Catalysts
Track AUPH earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
AUPH Dividend Analysis
AUPH dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
AUPH Financial Data
AUPH revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
AUPH Risk Analysis
AUPH volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
AUPH Stock News
AUPH stock news, market tone, recent headlines, and catalyst context.
AUPH vs Biotechnology Peers
Current peer cohort: AUPH · AVBP · AXSM · BBIO · BCRX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| AUPH Current stock | 75/100 | 84/100 | 73/100 | 68/100 | 0.16 | 35.52% | Current |
| AVBP ArriVent BioPharma, Inc. | 35/100 | — | 23/100 | 32/100 | -0.08 | 81.51% | AUPH vs AVBP |
| AXSM Axsome Therapeutics, Inc. | 47/100 | 65/100 | 24/100 | 57/100 | 0.2 | 45.79% | AUPH vs AXSM |
| BBIO BridgeBio Pharma, Inc. | 64/100 | 55/100 | 69/100 | 62/100 | 0.55 | 44.14% | AUPH vs BBIO |
| BCRX BioCryst Pharmaceuticals, Inc. | 59/100 | 86/100 | 42/100 | 55/100 | 0.36 | 48.06% | AUPH vs BCRX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for AUPH: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching AUPH
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for AUPH
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
AUPH Stock FAQ
What is AUPH stock price today?
Aurinia Pharmaceuticals Inc.'s current stock price is $15.73. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is AUPH bullish or bearish right now?
AUPH's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is AUPH's market cap?
AUPH's market cap is $2.1B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is AUPH's current P/E ratio?
AUPH's current P/E ratio is 6.64 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is AUPH's RSI?
AUPH's 14-day RSI is 39.95 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is AUPH above its 50-day and 200-day moving averages?
AUPH is -4.55% from its 50-day SMA and -0.00% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is AUPH's next earnings date?
AUPH's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does AUPH pay a dividend?
AUPH's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.